未登录

K

Kashyap Patel

University of Exeter

H指数:22

被引数:1,590

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Identification of the ACTB p.Ser348Leu de novo variant in individuals with syndromic neonatal diabetes

在综合征性新生儿糖尿病个体中鉴定出ACTB p.Ser348Leu新发变异

IF10.8

2026-05-090

OAAI

Impact of using time-averaged exposure metrics on binary endpoints in exposure-response analyses

使用时间平均暴露指标对暴露-反应分析中二元终点的影响

FRONTIERS IN PHARMACOLOGY

IF4.8

2025-01-160

OA

The use of quantitative clinical pharmacology approaches to support moxidectin dosing recommendations in lactation

PLOS NEGLECTED TROPICAL DISEASES

IF3.4

2024-08-051

OAAI

Population Pharmacokinetics of trastuzumab deruxtecan (T-DXd) in HER2positive breast cancer subjects: analyses across 12 Phase 1-3 studies

CANCER RESEARCH

IF16.6

2024-05-020

PRE

Application of the model-informed drug development paradigm to datopotamab deruxtecan dose selection for late-stage development

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2023-11-010

OA

Assessing the Combined Public Health Impact of Pharmaceutical Interventions on Pandemic Transmission and Mortality: An Example in SARS CoV-2

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2022-09-201

OAAI

Model-informed drug repurposing: A pharmacometric approach to novel pathogen preparedness, response and retrospection

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2021-02-2310

OAAI

Using in silico viral kinetic models to guide therapeutic strategies during a pandemic: An example in SARS-CoV-2

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2021-01-155

OAAI

Pharmacologic effects of oseltamivir in immunocompromised adult patients as assessed by population PK/PD analysis and drug-disease modelling for dosing regimen optimization

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2020-09-095

OAAI

Respiratory syncytial virus-A dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humans

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

IF3.6

2018-10-2921

OA

Optimizing vancomycin dosage regimens in relation to high-flux haemodialysis

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

IF3.6

2018-09-1112

OAAI

A Regression Approach to Visual Predictive Checks for Population Pharmacometric Models

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2018-09-1014

OAAI

Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?

IF9.3

2015-12-01109

OAAI

Pharmacokinetics and safety of oseltamivir in patients with end-stage renal disease treated with automated peritoneal dialysis

自动腹膜透析治疗终末期肾病患者奥司他韦的药代动力学和安全性

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2015-03-2310

OAAI

Modelling the time course of antimalarial parasite killing: a tour of animal and human models, translation and challenges

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2014-12-1914

OAAI

Malignant melanoma of the gastro-intestinal tract: A case series

胃肠道的恶性黑色素瘤: 病例系列

INTERNATIONAL JOURNAL OF SURGERY

IF10.1

2014-05-0120

OAAI

Pulmonary and Systemic Pharmacokinetics of Inhaled and Intravenous Colistin Methanesulfonate in Cystic Fibrosis Patients: Targeting Advantage of Inhalational Administration

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2014-05-01143

OAAI

Predicting the parasite killing effect of artemisinin combination therapy in a murine malaria model

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

IF3.6

2014-04-2814

OA

Population Pharmacokinetics of Colistin Methanesulfonate in Rats: Achieving Sustained Lung Concentrations of Colistin for Targeting Respiratory Infections

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2013-10-0151

OA

A Time-to-Event Pharmacodynamic Model Describing Treatment Response in Patients with Pulmonary Tuberculosis Using Days to Positivity in Automated Liquid Mycobacterial Culture

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2013-02-0134

OAAI